These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 29676460)

  • 21. Entinostat-Bortezomib Hybrids against Multiple Myeloma.
    Ferro A; Graikioti D; Gezer E; Athanassopoulos CM; Cuendet M
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Research Progress on Molecular Mechanisms of Resistance to Bortezomib in Multiple Myeloma- Review].
    Shi LL; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1576-1579. PubMed ID: 29070146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapies for multiple myeloma.
    Wallington-Beddoe CT; Pitson SM
    Aging (Albany NY); 2017 Aug; 9(8):1857-1858. PubMed ID: 28854147
    [No Abstract]   [Full Text] [Related]  

  • 24. Proteasome inhibitors in the treatment of multiple myeloma.
    McBride A; Ryan PY
    Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibition and multiple myeloma.
    Kanagasabaphy P; Morgan GJ; Davies FE
    Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma.
    Manasanch EE; Korde N; Zingone A; Tageja N; Fernandez de Larrea C; Bhutani M; Wu P; Roschewski M; Landgren O
    Leuk Lymphoma; 2014 Aug; 55(8):1707-14. PubMed ID: 24261677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging therapies targeting the ubiquitin proteasome system in cancer.
    Weathington NM; Mallampalli RK
    J Clin Invest; 2014 Jan; 124(1):6-12. PubMed ID: 24382383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the UPS as therapy in multiple myeloma.
    Chauhan D; Bianchi G; Anderson KC
    BMC Biochem; 2008 Oct; 9 Suppl 1(Suppl 1):S1. PubMed ID: 19007431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of proteasome inhibitors for treatment of multiple myeloma.
    Schlafer D; Shah KS; Panjic EH; Lonial S
    Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future agents and treatment directions in multiple myeloma.
    Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
    Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
    Dolloff NG
    Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New pharmacotherapy options for multiple myeloma.
    Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
    Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms in multiple myeloma drug resistance.
    Nikesitch N; Ling SC
    J Clin Pathol; 2016 Feb; 69(2):97-101. PubMed ID: 26598624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
    Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of novel agents in multiple myeloma patients with hepatic impairment.
    Stansfield LC; Gonsalves WI; Buadi FK
    Future Oncol; 2015; 11(3):501-10. PubMed ID: 25675129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
    Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
    Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.